Literature DB >> 1729183

Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.

S V Hetherington1, C C Patrick.   

Abstract

Antibodies directed against the capsular polysaccharide (polyribosyl ribitol phosphate [PRP]) or the outer membrane proteins (OMP) of Haemophilus influenzae type b (Hib) promote bactericidal activity, complement 3 (C3) binding, and ingestion by phagocytic cells. To assess the relative contribution of anti-OMP to host defense against Hib, we compared the opsonic activities of anti-PRP and anti-OMP as reflected by the amounts of C3 bound to the bacterial surface. Immunoglobulin G (IgG) fractions containing either anti-PRP or anti-OMP were incubated with Hib in the presence of a C5-deficient complement source. C3, total IgG, and IgG subclasses bound to the bacteria were quantified by enzyme-linked immunosorbent assay. The maximum amount of C3 which could be bound to Hib was greater in the presence of anti-PRP than in the presence of anti-OMP. Also, except at low IgG concentrations, the rate of increase in bound C3 as a function of increasing IgG concentration was greater for anti-PRP than for anti-OMP. Hib-bound anti-OMP consisted primarily of IgG1 and IgG3, whereas bound anti-PRP was primarily IgG1 and IgG2. Thus, the potential for C3 binding to Hib is greater in the presence of anti-PRP than in the presence of anti-OMP, probably because of the larger number of binding sites available to the former. Nonetheless, OMP appear to provide important targets for opsonic antibody and would be logical components of a PRP-conjugate vaccine or may be efficacious as vaccines against nontypeable H. influenzae.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729183      PMCID: PMC257497          DOI: 10.1128/iai.60.1.19-24.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1- to 6-month-old infants.

Authors:  D V Madore; C L Johnson; D C Phipps; L A Popejoy; R Eby; D H Smith
Journal:  Pediatrics       Date:  1990-03       Impact factor: 7.124

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Target antigens for bactericidal and opsonizing antibodies to Haemophilus influenzae.

Authors:  T Dahlberg-Lagergård
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1982-08

4.  The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity.

Authors:  S Shaw; A L Smith; P Anderson; D H Smith
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

5.  Further studies of the role of noncapsular antibody in protection against experimental Haemophilus influenzae type b bacteremia.

Authors:  J L Shenep; R S Munson; S J Barenkamp; D M Granoff
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

6.  A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4.

Authors:  K A Joiner; R Goldman; M Schmetz; M Berger; C H Hammer; M M Frank; L Leive
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

7.  Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins.

Authors:  H E Gnehm; S I Pelton; S Gulati; P A Rice
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study.

Authors:  W F Schlech; J I Ward; J D Band; A Hightower; D W Fraser; C V Broome
Journal:  JAMA       Date:  1985 Mar 22-29       Impact factor: 56.272

9.  The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.

Authors:  E J Brown; K A Joiner; T A Gaither; C H Hammer; M M Frank
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

10.  Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of Haemophilus influenzae type b.

Authors:  J R Schreiber; V Barrus; K L Cates; G R Siber
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

View more
  4 in total

1.  Outer membrane protein binding sites of complement component 3 during opsonization of Haemophilus influenzae.

Authors:  S V Hetherington; C C Patrick; E J Hansen
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

Review 2.  Hidden risks for pneumonia in Malawi.

Authors:  D G Fullerton; S B Gordon
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

3.  DNA sequence analysis and restriction fragment length polymorphisms of the P1 gene of Haemophilus influenzae biogroup aegyptius associated with Brazilian purpuric fever.

Authors:  R B Reed; J B Frost; K Kort; S D Myers; A J Lesse
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

4.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.